Phase II Trial of High-Dose Bevacizumab in the Treatment of Patients With Advanced Clear Cell Renal Carcinoma
Bevacizumab is considered a targeted drug. Targeted drugs act on specific receptors on a
cell. Bevacizumab blocks receptors that help cancer cells develop blood supplies so that
the cancer can grow. These specific receptors are found in greater numbers in kidney
cancer. In that regard bevacizumab will be tested in 2 doses that are higher than
non-kidney cancer treatments with bevacizumab.
One group of patients will receive bevacizumab at 15 mg per kg by vein every 2 weeks. A
total of 75 patients will be treated with this dose.
If this dose is well tolerated a second group of patients will receive bevacizumab at 15mg
per kg by vein weekly.
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
John D. Hainsworth, M.D.
Sarah Cannon Research Institute
United States: Food and Drug Administration
SCRI GU 43
|Florida Cancer Specialists||Fort Myers, Florida 33901|
|University of Pittsburgh Medical Center||Pittsburgh, Pennsylvania 15213|
|Northeast Georgia Medical Center||Gainesville, Georgia 30501|
|Spartanburg Regional Medical Center||Spartanburg, South Carolina 29303|
|Consultants in Blood Disorders and Cancer||Louisville, Kentucky 40207|
|Family Cancer Center||Collierville, Tennessee 38017|
|Methodist Cancer Center||Omaha, Nebraska 68114|
|Peninsula Cancer Institute||Newport News, Virginia 23601|
|Center for Cancer and Blood Disorders||Bethesda, Maryland 20817|
|Cancer Care of Western North Carolina||Asheville, North Carolina 28801|
|Tennessee Oncology, PLLC||Clarksville, Tennessee 37043|
|Oncology Hematology Care||Cincinnati, Ohio 45242|
|Chattanooga Oncology Hematology Associates||Chattanooga, Tennessee 37404|